Validation of the US Food and Drug Administration's COVID‐19 Disease Severity Categorization for Use in Real‐World Data

The US Food and Drug Administration proposed a five‐level disease severity categorization for baseline COVID‐19 (asymptomatic, mild, moderate, severe, critical).

• Publication year

  2025

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2025-11-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1002/pds.70252PMID 41208338
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validation of algorithms in studies based on routinely collected health data: general principles.

  2024cited by this paper
• Self-administered versus clinician-performed BinaxNOW COVID rapid test: a comparison of accuracy

  2024cited by this paper
• COVID-19 severity scale for claims data research

  2023cited by this paper
• Stratified Sampling

  2022cited by this paper
• Core concepts in pharmacoepidemiology: Validation of health outcomes of interest within real‐world healthcare databases

  2022cited by this paper
• Categorization of COVID‐19 severity to determine mortality risk

  2022cited by this paper
• Use of an EHR to inform an administrative data algorithm to categorize inpatient COVID-19 severity

  2021cited by this paper
• Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the pre-vaccine period.

  2021cited by this paper
• Positive Predictive Value of COVID-19 ICD-10 Diagnosis Codes Across Calendar Time and Clinical Setting

  2021cited by this paper
• Validation of diagnosis codes to identify hospitalized COVID‐19 patients in health care claims data

  2021cited by this paper
• Uptake and Accuracy of the Diagnosis Code for COVID-19 Among US Hospitalizations.

  2020cited by this paper
• Natural history of COVID-19: Risk factors for hospitalizations and deaths among >26 million U.S. Medicare beneficiaries

  2020cited by this paper
• A New Interpretation of the Weighted Kappa Coefficients

  2016cited by this paper
• Evaluation Measures for Ordinal Regression

  2009cited by this paper
• Pharmacoepidemiology and drug safety

  2001cited by this paper
• The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

  1996cited by this paper
• Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.

  1968cited by this paper
• Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit.

  1968cited by this paper

• No citing papers are available for this paper.